ELISA
EGF (Epidermal growth factor) exerts its actions by binding to the EGF Receptor, a 170 kDa protein kinase. Activation of EGFR initiates diverse cellular pathways in response to toxic environmental stimuli, or to EGF binding to the receptor, the EGFR forms homo- or heterodimers with other family members. Each dimeric receptor complex initiates a distinct signaling pathway by recruiting different Src homology 2 (SH2) containing effector proteins. EGF is far and wide expressed in kidney, cerebrum, prostrate and salivary glands. EGF acts as a potent mitogenic factor and the phosphorylated receptor recruits adapter proteins like GRB2 that activates complex downstream signaling cascades. EGF activates at least 4 major downstream signaling cascades including the RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STAT modules. Research studies suggest the protein may also play important role in activating the NF-kappa-B signaling cascade. Defects in the EGGF gene are the cause of hypomagnesemia type 4 and dysregulation has been associated with the growth and progression of certain cancers.
| Marque | Invitrogen |
|---|---|
| Réf. B-LABO | BL-RE-091845 |
| Réf. fabricant | 17879135 |
| Numéro d’adhésion | P07522 |
| Type de produit | ELISA |
| Identification génétique (Entrez) | 25313 |
| Symbole de gène(s) | EGF |
| Quantité | 10 x 96 Tests |
| État réglementaire | RUO |
| Conditions de stockage | Refer to product documentation for component specific storage temperature. |
| Cible | Rat |
